Afinitor (Page 12 of 12)
PRINCIPAL DISPLAY PANEL
NDC 0078-0594-51
Rx only
28 Tablets
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR® (everolimus) tablets
Each tablet contains
2.5 mg
everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0566-51
Rx only
28 Tablets
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR® (everolimus) tablets
Each tablet contains
5 mg
everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0620-51
Rx only
28 Tablets
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR® (everolimus) tablets
Each tablet contains
7.5 mg
everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0567-51
Rx only
28 Tablets
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR® (everolimus) tablets
Each tablet contains
10 mg
everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0626-51
Rx only
28 Tablets for Oral Suspension
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR DISPERZ® (everolimus tablets for oral suspension)
2 mg
TABLETS MUST BE DISPERSED IN WATER.
TABLETS MUST NOT BE SWALLOWED WHOLE, CHEWED OR CRUSHED.
Each tablet contains 2 mg everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0627-51
Rx only
28 Tablets for Oral Suspension
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR DISPERZ® (everolimus tablets for oral suspension)
3 mg
TABLETS MUST BE DISPERSED IN WATER.
TABLETS MUST NOT BE SWALLOWED WHOLE, CHEWED OR CRUSHED.
Each tablet contains 3 mg everolimus
NOVARTIS
PRINCIPAL DISPLAY PANEL
NDC 0078-0628-51
Rx only
28 Tablets for Oral Suspension
Carton contains 4 individual blister cards of 7 tablets.
AFINITOR DISPERZ® (everolimus tablets for oral suspension)
5 mg
TABLETS MUST BE DISPERSED IN WATER.
TABLETS MUST NOT BE SWALLOWED WHOLE, CHEWED OR CRUSHED.
Each tablet contains 5 mg everolimus
NOVARTIS
AFINITOR everolimus tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
AFINITOR everolimus tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
AFINITOR everolimus tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
AFINITOR everolimus tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
AFINITOR DISPERZ everolimus tablet, for suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
AFINITOR DISPERZ everolimus tablet, for suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
AFINITOR DISPERZ everolimus tablet, for suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
Labeler — Novartis Pharmaceuticals Corporation (002147023) |
Revised: 08/2023 Novartis Pharmaceuticals Corporation
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.